Mobile Lung Cancer Screening

Recruiting

• Conditions: Lung Cancer Prevention

• Registration Number: NCT07015151
• Lead Sponsor: Hospices Civils de Lyon

Brief Summary

Lung cancer screening using low-dose CT (LDCT) has been shown to reduce mortality in high-risk populations. In 2022, the French National Cancer Institute (INCa) issued guidelines recommending screening for individuals aged 50-74 with a history of heavy smoking, including current smokers or those who quit less than 15 years ago. A national pilot program (IMPULSION) will be launched in 2025.

Lung cancer incidence is strongly correlated with socioeconomic status, yet underserved populations remain difficult to engage in screening programs. Mobile health units using a "reach-out" strategy have demonstrated effectiveness in other countries (UK, Brazil, USA). In France, this approach has been used for breast cancer screening via mobile mammography units.

The MobILYAD project aims to compare two screening modalities- a mobile demedicalized unit (CT-equipped van with trained nurses) and a conventional hospital-based unit- to assess the effectiveness of mobile screening in reaching socially disadvantaged populations.

Detailed Description

Not available

Study Timeline

• Study First Submitted: 2025-06-03
• Study First Submitted QC: 2025-06-03
• Study First Posted: 2025-06-11
• Study Start: 2025-06-12
• Status Verified: 2025-09
• Last Update Submitted: 2025-09-02
• Last Update Posted: 2025-09-09
• Primary Completion: 2028-09
• Study Completion: 2028-09-01

Recruitment & Eligibility

• Status: RECRUITING
• Sex: All
• Target Recruitment: 4312

Inclusion Criteria

Not provided

Exclusion Criteria

Not provided

Study & Design

• Study Type: OBSERVATIONAL
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
Proportion of socially deprived participants included in the mobile screening group	Baseline (Day 0)	The percentage of participants with an EPICES score ≥ 4 (indicating social vulnerability) in the mobile screening arm, compared to the non-mobile arm.

Secondary Outcome Measures

Name	Time	Method
Feasibility of task-shifting to nurses	Throughout inclusion period	Rate of recourse to a physician and participant satisfaction in each modality.
Adherence to intermediate CT scans	Month 1, Month 3, Month 6 if clinically indicated	Proportion of participants who undergo intermediate follow-up CTs when required.
Rate of positive screening	Up to 3 months post-initial CT	Proportion of participants with positive CT findings and subsequent medical workup.
Lung cancer incidence	Over 12 months	Number and percentage of participants diagnosed with lung cancer during the 12-month follow-up.
COPD detection relevance	Baseline and 12 months	Rate of new COPD diagnoses and associated therapeutic modifications; respiratory morbidity and mortality over 12 months.
Cardiovascular risk detection relevance	Baseline and 12 months	Rate of high-risk participants identified, therapeutic implications, cardiovascular events over follow-up.
Creation of biobank (Bio-ILYAD)	At inclusion	Proportion of participants consenting to blood and exhaled air sample collection for future biomarker research.
Lung cancer staging	Within 12 months	Distribution of lung cancer cases by stage at diagnosis (I-IV), as recorded in clinical reports. Number of participants per stage
Histological type of diagnosed lung cancers	Within 12 month	Categorization of diagnosed lung cancers by histological type (e.g., adenocarcinoma, squamous cell carcinoma, small cell). Number of participants per histological category
Initial treatment of diagnosed lung cancers	Within 3 months of diagnosis	Description and frequency of initial treatment modalities (e.g., surgery, radiotherapy, systemic therapy). Number of participants per treatment type
Participation by socio-demographic profile	Inclusion	Comparison of participants' characteristics between the two modalities (smoking status, age, sex, socio-professional category, income level, education, perceived ethnic identity, geographic isolation, presence of a general practitioner).
Mobile feasibility	Throughout inclusion period	Feasibility of the mobile screening pathway, assessed by the attendance rate (proportion of invited participants who attend the mobile unit) and the completion rate (proportion of those attendees who complete the full screening process). Both will be reported separately as percentages.; Unit of Measure: Percentage of participants (%)
Adherence to 12-month CT scan	At Month 12	Proportion of participants who complete the scheduled CT scan at one year.
Adherence to tobacco cessation consultations	Over 12 months	Proportion of active smokers who attend the initial and, if applicable, follow-up cessation visits.
Smoking cessation success	At 12 months	Self-reported complete tobacco cessation at 12 months.

Trial Locations

Locations (2)

" Centre de dépistage mobile " - Hôpital Lyon Sud; 🇫🇷 Pierre-Bénite, France

Service de Pneumologie " Centre de dépistage non mobile " - Hôpital Lyon Sud; 🇫🇷 Pierre-Bénite, France